1. Market Research
  2. > Herpes Infections - Pipeline Review, H1 2013

Herpes Infections - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 310 pages

Herpes Infections - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Herpes Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Herpes Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Herpes Infections. Herpes Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Herpes Infections.
- A review of the Herpes Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Herpes Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Herpes Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Herpes Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Herpes Infections - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Herpes Infections Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Herpes Infections 13
Herpes Infections Therapeutics under Development by Companies 15
Herpes Infections Therapeutics under Investigation by Universities/Institutes 21
Late Stage Products 23
Comparative Analysis 23
Mid Clinical Stage Products 24
Comparative Analysis 24
Early Clinical Stage Products 25
Comparative Analysis 25
Discovery and Pre-Clinical Stage Products 26
Comparative Analysis 26
Herpes Infections Therapeutics - Products under Development by Companies 27
Herpes Infections Therapeutics - Products under Investigation by Universities/Institutes 33
Companies Involved in Herpes Infections Therapeutics Development 34
Vical Incorporated 34
Sanofi-Aventis 35
GlaxoSmithKline plc 36
Genentech, Inc. 37
Antigenics, Inc. 38
GenVec, Inc. 39
Merck and Co., Inc. 40
Novartis AG 41
Isotechnika Pharma Inc. 42
Astellas Pharma Inc. 43
Novavax, Inc. 44
Alfacell Corporation 45
CEL-SCI Corporation 46
4SC AG 47
Intercell AG 48
Mymetics Corporation 49
NanoViricides, Inc. 50
Nutra Pharma Corporation 51
Peregrine Pharmaceuticals, Inc. 52
Pevion Biotech Ltd 53
Alnylam Pharmaceuticals, Inc 54
Flamel Technologies S.A. 55
Starpharma Holdings Limited 56
Green Cross Corporation 57
BioAlliance Pharma SA 58
Oryzon 59
Functional Genetics, Inc. 60
Colby Pharmaceutical Company 61
Nutri Pharma ASA 62
Pharmagenesis, Inc. 63
Foamix Ltd. 64
Vironova AB 65
Altor BioScience Corporation 66
Cellectis S.A. 67
Phoenix Biotechnology, Inc. 68
Osel Inc. 69
Arcion Therapeutics, Inc. 70
AiCuris GmbH and Co. KG 71
Cell Medica Limited 72
AlphaVax, Inc. 73
Romark Laboratories, L.C. 74
Chimerix, Inc. 75
aRigen Pharmaceuticals, Inc. 76
Lumavita AG 77
Theraclone Sciences, Inc. 78
Sinovac Biotech Ltd. 79
Wittycell S.A.S. 80
Microbiotix, Inc. 81
NanoBio Corporation 82
PharmaNova Inc. 83
ImmunoVaccine Technologies Inc. 84
Immune Design Inc. 85
Redox Pharmaceutical Corporation 86
PepTcell Limited 87
4-Antibody AG 88
Epiphany Biosciences, Inc. 89
Cannabis Science, Inc. 90
Vaxart, Inc. 91
Synergy Pharmaceuticals, Inc. 92
Genocea Biosciences, Inc. 93
Variation Biotechnologies, Inc. 94
AIMM Therapeutics B.V. 95
Profectus BioSciences, Inc. 96
China National Pharmaceutical Group Corporation 97
Trellis Bioscience, Inc. 98
CONRAD 99
Vakzine Projekt Management GmbH 100
Spider Biotech S.r.l. 101
Kala Pharmaceuticals 102
Beech Tree Labs, Inc. 103
Coridon Pty Ltd 104
Herpes Infections - Therapeutics Assessment 105
Assessment by Monotherapy Products 105
Assessment by Combination Products 106
Assessment by Route of Administration 107
Assessment by Molecule Type 110
Drug Profiles 112
maribavir - Drug Profile 112
FV-100 - Drug Profile 114
CyMVectin - Drug Profile 116
CMX001 - Drug Profile 117
CMX001 - Drug Profile 119
acyclovir - Drug Profile 121
TCN-202 - Drug Profile 122
RPI-78M - Drug Profile 123
RPI-MN - Drug Profile 125
ASP-0113 - Drug Profile 127
ASP-0113 - Drug Profile 128
CEL-1000 - Drug Profile 129
CTC-96 - Drug Profile 131
HSV Vaccine - Drug Profile 132
NB-001 - Drug Profile 133
LMV-601 - Drug Profile 135
Antiviral TCR-Ck - Drug Profile 136
Antiviral TCR-Ig - Drug Profile 137
4Ab-028 - Drug Profile 138
HSV-2 Vaccine - Drug Profile 139
HSV-2 Vaccine - Drug Profile 140
AVX-601 - Drug Profile 141
HerpV Vaccine - Drug Profile 143
AIC-316 - Drug Profile 144
valomaciclovir stearate - Drug Profile 145
VPM-2001 - Drug Profile 147
Donor-Derived CMV-pp65 Peptide-Specific T Cells - Drug Profile 148
Small Interference Ribonucleic Acids - Drug Profile 150
letermovir - Drug Profile 151
astodrimer - Drug Profile 152
ACAM-529 - Drug Profile 154
acyclovir SR - Drug Profile 156
GSK-1437173A - Drug Profile 158
RNAi Therapeutic For HSV Infection - Drug Profile 160
BTL-TML-HSV - Drug Profile 161
Cytovir CMV - Drug Profile 162
HCMV Specific CTL - Drug Profile 163
V-212 - Drug Profile 165
tenofovir - Drug Profile 167
MucoCept Platform - Drug Profile 169
HSV-2 Px - Drug Profile 170
Varicella Zoster Virus Vaccine - Drug Profile 171
Live Attenuated Human Cytomegalovirus (HCMV) Vaccine - Drug Profile 172
CMV Specific T Cell Donor Lymphocyte - Drug Profile 173
HLA Matched Allogeneic Virus Specific Cytotoxic T Lymphocytes - Drug Profile 174
RBT-301 - Drug Profile 176
Chickenpox Vaccine - Drug Profile 177
JVRS-100 + Herpes Simplex Virus-2 Vaccine - Drug Profile 178
CMV Vaccine - Drug Profile 179
Cytomegalovirus Vaccine - Drug Profile 180
New Thiazolides - Drug Profile 181
Drug For Herpes Simplex - Drug Profile 182
P-31 - Drug Profile 183
rAmphinase-2 - Drug Profile 184
MBX-400 - Drug Profile 186
vif1 Peptide - Drug Profile 188
RG-7667 - Drug Profile 189
Multi-Virus Cytotoxic T Lymphocytes - Drug Profile 190
PGN-632 - Drug Profile 191
ID-G103 - Drug Profile 192
PN-200 - Drug Profile 193
LSD-1 Inhibitor For HSV - Drug Profile 194
PN-201 - Drug Profile 195
Human Cytomegalovirus Antibodies - Drug Profile 196
HSV Program - Drug Profile 197
HerpeCide-I - Drug Profile 198
acyclovir - Drug Profile 199
CMV-345 - Drug Profile 200
CS-TATI-1 Research Program - Drug Profile 201
SB-105 - Drug Profile 202
Human Monoclonal Antibodies Program For CMV - Drug Profile 203
WTCa Adjuvant - Drug Profile 204
WTCb Adjuvant - Drug Profile 206
WTCn Adjuvant - Drug Profile 208
Nonimmunosuppressive Cyclosporin Analog Molecule Program - Drug Profile 210
PG-36 - Drug Profile 212
sattabacin - Drug Profile 213
Plantibodies - Drug Profile 214
Drug For Cytomegalovirus - Drug Profile 215
Azuvirins - Drug Profile 216
RC-100b - Drug Profile 217
Drug For Herpes Simplex Virus - Drug Profile 218
Herpes Simplex Virus 2 Vaccine - Drug Profile 219
Antiviral Agents - Drug Profile 220
Herpes Simplex Virus 2 Vaccine - Drug Profile 221
HSPG-Containing Infection Complex Antagonists - Drug Profile 222
SB105-A10 - Drug Profile 223
Phosphonate Derivatives - Drug Profile 225
Simplexia Program - Drug Profile 226
CJ-40005 - Drug Profile 228
CJ-40007 - Drug Profile 229
PEV-10 - Drug Profile 230
Drug 1 For Human Cytomegalovirus Infection - Drug Profile 231
Drug 2 For Human Cytomegalovirus Infection - Drug Profile 232
Drug 3 For Human Cytomegalovirus Infection - Drug Profile 233
Dual Active Cytomegalovirus (CMV)/Polyomavirus BK (BKV) Program - Drug Profile 234
MB-66 - Drug Profile 235
MG-1111 - Drug Profile 236
4SC-302 - Drug Profile 237
MAb Against HCMV - Drug Profile 238
MAb Against HSV-1/2 - Drug Profile 239
Herpes Simplex Virus Type 2 Vaccine - Drug Profile 240
Labyrinthopeptine A1 - Drug Profile 241
ZEP-3 - Drug Profile 242
Cell Therapy For CMV - Drug Profile 244
Fatty Alcohol Substituted Nucleoside Derivatives - Drug Profile 245
acyclovir - Drug Profile 246
Herpes Infections Therapeutics - Drug Profile Updates 247
Herpes Infections Therapeutics - Discontinued Products 283
Herpes Infections Therapeutics - Dormant Products 284
Herpes Infections - Product Development Milestones 292
Featured News and Press Releases 292
Appendix 302
Methodology 302
Coverage 302
Secondary Research 302
Primary Research 302
Expert Panel Validation 302
Contact Us 303
Disclaimer 303

List of Tables


Number of Products Under Development for Herpes Infections, H1 2013 20
Products under Development for Herpes Infections - Comparative Analysis, H1 2013 21
Number of Products under Development by Companies, H1 2013 23
Number of Products under Development by Companies, H1 2013 (Contd..1) 24
Number of Products under Development by Companies, H1 2013 (Contd..2) 25
Number of Products under Development by Companies, H1 2013 (Contd..3) 26
Number of Products under Development by Companies, H1 2013 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H1 2013 29
Comparative Analysis by Late Stage Development, H1 2013 30
Comparative Analysis by Mid Clinical Stage Development, H1 2013 31
Comparative Analysis by Early Clinical Stage Development, H1 2013 32
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 33
Products under Development by Companies, H1 2013 34
Products under Development by Companies, H1 2013 (Contd..1) 35
Products under Development by Companies, H1 2013 (Contd..2) 36
Products under Development by Companies, H1 2013 (Contd..3) 37
Products under Development by Companies, H1 2013 (Contd..4) 38
Products under Development by Companies, H1 2013 (Contd..5) 39
Products under Investigation by Universities/Institutes, H1 2013 40
Vical Incorporated, H1 2013 41
Sanofi-Aventis, H1 2013 42
GlaxoSmithKline plc, H1 2013 43
Genentech, Inc., H1 2013 44
Antigenics, Inc., H1 2013 45
GenVec, Inc., H1 2013 46
Merck and Co., Inc., H1 2013 47
Novartis AG, H1 2013 48
Isotechnika Pharma Inc., H1 2013 49
Astellas Pharma Inc., H1 2013 50
Novavax, Inc., H1 2013 51
Alfacell Corporation, H1 2013 52
CEL-SCI Corporation, H1 2013 53
4SC AG, H1 2013 54
Intercell AG, H1 2013 55
Mymetics Corporation, H1 2013 56
NanoViricides, Inc., H1 2013 57
Nutra Pharma Corporation, H1 2013 58
Peregrine Pharmaceuticals, Inc., H1 2013 59
Pevion Biotech Ltd, H1 2013 60
Alnylam Pharmaceuticals, Inc, H1 2013 61
Flamel Technologies S.A., H1 2013 62
Starpharma Holdings Limited, H1 2013 63
Green Cross Corporation, H1 2013 64
BioAlliance Pharma SA, H1 2013 65
Oryzon, H1 2013 66
Functional Genetics, Inc., H1 2013 67
Colby Pharmaceutical Company, H1 2013 68
Nutri Pharma ASA, H1 2013 69
Pharmagenesis, Inc., H1 2013 70
Foamix Ltd., H1 2013 71
Vironova AB, H1 2013 72
Altor BioScience Corporation, H1 2013 73
Cellectis S.A., H1 2013 74
Phoenix Biotechnology, Inc., H1 2013 75
Osel Inc., H1 2013 76
AiCuris GmbH and Co. KG, H1 2013 78
Cell Medica Limited, H1 2013 79
AlphaVax, Inc., H1 2013 80
Romark Laboratories, L.C., H1 2013 81
Chimerix, Inc., H1 2013 82
aRigen Pharmaceuticals, Inc., H1 2013 83
Lumavita AG, H1 2013 84
Theraclone Sciences, Inc., H1 2013 85
Sinovac Biotech Ltd., H1 2013 86
Wittycell S.A.S., H1 2013 87
Microbiotix, Inc., H1 2013 88
NanoBio Corporation, H1 2013 89
PharmaNova Inc., H1 2013 90
ImmunoVaccine Technologies Inc., H1 2013 91
Immune Design Inc., H1 2013 92
Redox Pharmaceutical Corporation, H1 2013 93
PepTcell Limited, H1 2013 94
4-Antibody AG, H1 2013 95
Epiphany Biosciences, Inc., H1 2013 96
Cannabis Science, Inc., H1 2013 97
Vaxart, Inc., H1 2013 98
Synergy Pharmaceuticals, Inc., H1 2013 99
Genocea Biosciences, Inc., H1 2013 100
Variation Biotechnologies, Inc., H1 2013 101
AIMM Therapeutics B.V., H1 2013 102
Profectus BioSciences, Inc., H1 2013 103
China National Pharmaceutical Group Corporation, H1 2013 104
Trellis Bioscience, Inc., H1 2013 105
CONRAD, H1 2013 106
Vakzine Projekt Management GmbH, H1 2013 107
Spider Biotech S.r.l., H1 2013 108
Kala Pharmaceuticals, H1 2013 109
Beech Tree Labs, Inc., H1 2013 110
Coridon Pty Ltd, H1 2013 111
Assessment by Monotherapy Products, H1 2013 112
Assessment by Combination Products, H1 2013 113
Assessment by Stage and Route of Administration, H1 2013 116
Assessment by Stage and Molecule Type, H1 2013 118
Herpes Infections Therapeutics - Drug Profile Updates 254
Herpes Infections Therapeutics - Discontinued Products 290
Herpes Infections Therapeutics - Dormant Products 291
Herpes Infections Therapeutics - Dormant Products (Contd..1) 292
Herpes Infections Therapeutics - Dormant Products (Contd..2) 293
Herpes Infections Therapeutics - Dormant Products (Contd..3) 294
Herpes Infections Therapeutics - Dormant Products (Contd..4) 295
Herpes Infections Therapeutics - Dormant Products (Contd..5) 296
Herpes Infections Therapeutics - Dormant Products (Contd..6) 297
Herpes Infections Therapeutics - Dormant Products (Contd..7) 298

List of Figures


Number of Products under Development for Herpes Infections, H1 2013 20
Products under Development for Herpes Infections - Comparative Analysis, H1 2013 21
Products under Development by Companies, H1 2013 22
Products under Investigation by Universities/Institutes, H1 2013 28
Late Stage Products, H1 2013 30
Mid Clinical Stage Products, H1 2013 31
Early Clinical Stage Products, H1 2013 32
Discovery and Pre-Clinical Stage Products, H1 2013 33
Assessment by Monotherapy Products, H1 2013 112
Assessment by Combination Products, H1 2013 113
Assessment by Route of Administration, H1 2013 114
Assessment by Stage and Route of Administration, H1 2013 115
Assessment by Molecule Type, H1 2013 117
Assessment by Stage and Molecule Type, H1 2013 118

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.